ESMO 2024 | Exploring checkpoint inhibition in high-grade ER+ breast cancer
Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, gives an overview of findings from trials examining checkpoint inhibitors in high-grade ER+ breast cancer, particularly data from KEYNOTE-756 (NCT03725059) and CheckMate 7FL (NCT04109066). These trials assessed adding a checkpoint inhibitor to chemotherapy in the preoperative setting, showing improved pathologic complete response (PCR) rates. Future data on event-free survival (EFS) and biomarker analysis, especially for PD-L1, are needed to guide patient selection and confirm long-term benefits. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
